GTHX Key Statistics, Chart & Performance
The current stock price of GTHX is 7.15 USD. In the past month the price increased by 0.85%. In the past year, price increased by 481.3%.
GTHX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About GTHX
Company Profile
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 100 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Company Info
G1 THERAPEUTICS INC
700 Park Offices Drive, Suite 200
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: John E. Bailey Jr.
Employees: 100
Phone: 19192139835
G1 THERAPEUTICS INC / GTHX FAQ
Can you describe the business of G1 THERAPEUTICS INC?
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 100 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Can you provide the latest stock price for G1 THERAPEUTICS INC?
The current stock price of GTHX is 7.15 USD.
Does G1 THERAPEUTICS INC pay dividends?
GTHX does not pay a dividend.
What is the ChartMill rating of G1 THERAPEUTICS INC stock?
GTHX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GTHX stock?
11 analysts have analysed GTHX and the average price target is 7.29 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 7.15.
What sector and industry does G1 THERAPEUTICS INC belong to?
G1 THERAPEUTICS INC (GTHX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for G1 THERAPEUTICS INC?
G1 THERAPEUTICS INC (GTHX) has a market capitalization of 377.23M USD. This makes GTHX a Small Cap stock.
GTHX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GTHX. When comparing the yearly performance of all stocks, GTHX is one of the better performing stocks in the market, outperforming 99.79% of all stocks.
GTHX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GTHX. GTHX has a bad profitability rating. Also its financial health evaluation is rather negative.
GTHX Financial Highlights
Over the last trailing twelve months GTHX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 49.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.36% | ||
| ROE | -182.03% | ||
| Debt/Equity | 1.34 |
GTHX Forecast & Estimates
11 analysts have analysed GTHX and the average price target is 7.29 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 7.15.
For the next year, analysts expect an EPS growth of 55.71% and a revenue growth -8.96% for GTHX